Dopamine beta-monooxygenase
Dopamine beta-monooxygenase (DBM), also known as dopamine β-hydroxylase, is an enzyme that plays a critical role in the catecholamine biosynthesis pathway. This enzyme catalyzes the conversion of dopamine, a key neurotransmitter, into norepinephrine, another neurotransmitter that is essential for various physiological processes including stress response, heart rate regulation, and the sleep-wake cycle.
Function[edit | edit source]
Dopamine beta-monooxygenase is found primarily in the synaptic vesicles of neurons in the adrenal medulla and the central nervous system. The enzyme functions by hydroxylating the β-carbon of dopamine, using oxygen and ascorbic acid as cofactors, to produce norepinephrine. This reaction is vital for the synthesis of norepinephrine from dopamine and is a key step in the catecholamine biosynthesis pathway.
Structure[edit | edit source]
The enzyme is a monomer that contains copper as a cofactor, which is essential for its catalytic activity. The structure of dopamine beta-monooxygenase includes several domains that are critical for its function, including the binding sites for copper, oxygen, and the substrate dopamine. Mutations in the gene encoding this enzyme can affect its structure and function, leading to disorders related to catecholamine metabolism.
Clinical Significance[edit | edit source]
Alterations in the activity or expression of dopamine beta-monooxygenase can have significant clinical implications. Reduced activity of this enzyme has been associated with various neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, and certain forms of hypertension. Understanding the function and regulation of this enzyme is crucial for developing therapeutic strategies for these conditions.
Genetic Regulation[edit | edit source]
The gene encoding dopamine beta-monooxygenase is regulated by various factors, including stress and hormonal signals. This regulation ensures the appropriate synthesis of norepinephrine in response to physiological demands. Research into the genetic regulation of this enzyme may provide insights into the mechanisms underlying stress-related disorders and hypertension.
Pharmacology[edit | edit source]
Inhibitors of dopamine beta-monooxygenase have been explored as potential therapeutic agents for conditions such as hypertension and heart failure, where modulation of norepinephrine levels may be beneficial. However, the development of such drugs requires a thorough understanding of the enzyme's structure and function to avoid unwanted side effects.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD